G43.719 Insurance Policy Changes

ICD-10 G43.719 is officially defined as "Chronic migraine without aura, intractable, without status migrainosus." code G43.719 is referenced in 5 tracked payer policy changes from Aetna and Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code G43.719 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 26, 2026Medium impact
Pulsed Radiofrequency (CPB 0735, reviewed 2026-10-21)
Aetna's Clinical Policy Bulletin 0735 considers pulsed radiofrequency experimental, investigational, or unproven for all indications in its list, because its effectiveness has not been established. The list includes indications such as carpal tunnel syndrome, chronic knee pain, low back pain, trigeminal neuralgia, and headache. The policy also considers the Stimpod NMS460 nerve stimulator for post-amputation pain, combined ganglion impar block and pulsed radiofrequency for pudendal neuralgia, and combined platelet-rich plasma to the Gasserian ganglion and pulsed radiofrequency for trigeminal neuralgia experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Headaches: Nonsurgical Management (CPB 0462, reviewed 2026-07-23)
Aetna covers intravenous dihydroergotamine (DHE) for status migrainosus, for other intractable severe migraine attacks unresponsive to analgesics and triptans, and for cluster headache attacks that do not respond to oxygen or triptans, when given in the emergency room, hospital or urgent care setting, and covers it for medication overuse headache in the inpatient setting. Aetna also covers intramuscular ketorolac for short-term management of acute migraine (5 days or less), intramuscular and intravenous steroids and intravenous magnesium for acute migraines, caffeine citrate infusion for post lumbar puncture headache when the member is unable to take caffeine orally, and eptinezumab-jjmr (Vyepti) for preventive migraine treatment in an adult when the criteria are met. Aetna considers cranio-sacral therapy, intra-oral splints for tension-type headaches, IV DHE for other headache types, and a list of other nonsurgical migraine and cluster headache interventions experimental, investigational or unproven.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
State and School Employees' Health Insurance Plan - Botulinum Toxin
Botox (onabotulinumtoxinA) is the only covered botulinum toxin preparation for non-cosmetic indications under this policy. Dysport, Myobloc and Xeomin are considered not medically necessary because a formulary alternative is available. Botox may be considered medically necessary for overactive bladder, detrusor overactivity associated with a neurologic condition, chronic migraine prophylaxis, spasticity, cervical dystonia, primary axillary hyperhidrosis, blepharospasm, strabismus and spasmodic dysphonia when all criteria for the indication are met. Each indication has a 12-month length of approval and a maximum dose per 12 weeks. Revised criteria for detrusor overactivity, migraine prophylaxis and blepharospasm were approved by the Pharmacy and Therapeutics Committee on 05/26/2026.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Botulinum Toxin
Botox (onabotulinumtoxinA) is the only botulinum toxin the policy covers for non-cosmetic indications, and prior authorization is required. Dysport, Myobloc and Xeomin are currently considered not medically necessary because a formulary alternative is available. The policy was reviewed and approved on 05/26/2026, and that revision states that the use of samples will not be considered current or stable therapy and revises the maximum cumulative Botox dose for individuals treated for one or more indications.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Remote Electrical Neuromodulation for Migraines
Blue Cross & Blue Shield of Mississippi considers remote electrical neuromodulation (REN, such as Nerivio) medically necessary for the prevention of migraine when the listed criteria are met. Remote electrical neuromodulation for acute migraine is considered investigational. For individuals 8 to 17 years of age, the policy states that REN for migraine prevention may be considered medically necessary when the listed criteria are met.

Watch G43.719

Get one email when a payer policy names G43.719, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code G43.719?

There are 5 tracked policy changes affecting code G43.719, including updates from Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code G43.719?

Payers that have issued tracked updates for code G43.719 include: Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code G43.719 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code G43.719. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code G43.719?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Pulsed Radiofrequency (CPB 0735, reviewed 2026-10-21)

Headaches: Nonsurgical Management (CPB 0462, reviewed 2026-07-23)

State and School Employees' Health Insurance Plan - Botulinum Toxin

Botulinum Toxin

Remote Electrical Neuromodulation for Migraines

What insurance policy changes affect code G43.719?

Which payers have updated policy for code G43.719?

How do I get notified when code G43.719 policy changes?

Why do payers change policies for code G43.719?